Wednesday, 21 Aug 2019

You are here

Preview of EULAR 2019 Abstracts

EULAR 2019 begins today in Madrid and features over 2000 presentations.  After an initial review of titles and abstracts, I’ve compiled a hit list of presentations of interest to me and hopefully other practicing rheumatologists.  

EULAR will be rolling out many new “guidelines” reports including those addressing rheumatoid arthritis (RA) treatment; immune-related adverse events with checkpoint inhibitors, Sjogrens syndrome and more.

Late-breaking abstracts will be presented on Saturday morning (June 15th) and will include reports on filgotinib (Finch3), secukinumab (FUTURE 5), HLA-DRB1 alleles and responses to Abatacept or Adalimumab, Ultra-low dose rituximab and more.  

Here are some abstracts I’ll be watching (with links to EULAR Abstract site). Which of these interests you?

Abstract

Title

Comment

THU0337

Two regimens of Rituximab in Scleroderma associated interstitial lung disease

Appears to improve Lung function

OP0147

KAWAKINRA study: A pilot trial of anakinra in patients with IVIg-resistant Kawasaki disease

Rare disorder with good results in refractory disease. Dosing issues?

OP0180

Randomized, double blind, placebo controlled trial of Steroids in Hand OA

Looks like it works? But what about adverse effects?

OP0183

Riociguat in SSc associated ILD

 Anti-fibrotic drug shows some benefit in SSc lung disease

FRI0100

 

TOLEDEO study – Spacing ABA or TCZ to find the lowest effective dose in RA patients

Looks like less drug therapy carried a high risk of failure

FRI0537

Registry data on long-term outcomes and treatment efficacy in the TRAPS patients

IL-1 inhibitors much more effective than etanercept

FRI0282

Statins reduce relapse rates in Takayasu arteritis

A novel adjunctive therapy?

OP0025

Fenebrutinib vs. Adalimumab in RA

BTK inhibitor works in MTX- & TNF-IR patients

LB0009

Implated Vagal nerve stimulator in rheumatoid arthritis

Only 14 patients but novel, and looks effective

LB0002

Tildrakizumab in active PsA patients

Data on 3rd IL-23 inhibitor

OP0235

Maxmize Study: Secukinumab on Axial Manifestations in Psoriatic arthritis

Secukinumb works on the Axial outcomes of PsA pts with Spondylitis

FRI0458

 Measures of psoriasis severity and the risk of PsA

Skin severity predicts risk of PsA

SAT0388

 Characterization of psoriatic arthritis and nail psoriasis

 CORRONA - Nail disease predicts worse disease activity

OP0211

Ultrasound application in Extracranial GCA

 Axillary US correlates with PET findings

OP0165

EULAR recommendations for the management of irAE

 One of many EULAR recommendations at this meeting

SP0190

 EULAR Recommendations for the Management of Sjogrens 

 

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

RheumNow Podcast – Antibiotics Increase RA Risk (8.16.19)

Dr. Jack Cush reports the news and important journal articles from the past week on RheumNow.com.

RheumNow Podcast – Tricked Up Lupus Criteria (8.9.19)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com, including new SLE criteria, ULT in gout and MSU reductions, IVIG in ANCA vasculitis and non-TNF biologics outperform the TNF inhibitors.

EULAR Recommendations on Large Vessel Vasculitis

Th European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis (LVV) was originally published in 2009. Since then there have been new randomised clinical trials and cohort analyses leading to an update the original recommendations.

RheumNow Podcast – More Than a Spot of Tea (8.2.19)

Dr. Jack Cush reviews the journal articles and news reports from the past week on RheumNow.com: MMP-7 and Myositis-ILD; Post-surgical gout attacks; CV events and testosterone; and a Boxed warning for tofacitinib.

RheumNow Podcast – FDA Hyperactivity (7.26.19)

Dr. Jack Cush reviews the news, journal reports, and FDA releases and deliberations covered this past week on RheumNow.com